720 / 1631
Landmark (from EOI) OS analysis
*Patients who died or started a new anti-lymphoma treatment before EOI were excluded
Trotman J, et al. ICML 2017
OS* for non-CMR vs CMR status using Lugano 2014 criteria (N=519)
HR 0.22 (95% CI 0.11, 0.45); p<0.0001
CMR (n=451)
Non-CMR (n=68)
Censored
0.8
0.6
0.4
0.2
0
Time since end of treatment (months)
CMR
Non-CMR
Probability
0
6
12
18
24
30
36
42
48
60
54
451
68
445
64
438
61
429
58
423
55
346
50
249
36
169
28
76
12
3
83.8 (72.6, 90.7)
96.6 (94.4, 97.9)
1.0
No. of patients at risk